APLIF

Healthcare Biotechnology

Appili Therapeutics Inc.

$0.00

-0.00 -41.43% today

Price History

Not enough data

Key Stats

Market Cap

542,701.095

Avg Volume

3,884

EPS

-$0.03

52W High

$0.02

52W Low

$0.00

Div. Yield

0.0%

Valuation

Forward P/E

-0.08

P/B Ratio

-0.04

P/S Ratio

1.50

EV/EBITDA

-2.10

EV/Revenue

37.92

Margins

Gross Margin 100.0%

Operating Margin (1368.9%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(255.7%)

Liquidity & Leverage

Current Ratio

0.07

Quick Ratio

0.06

Total Cash

138,680

Total Debt

13.33M

About

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

appilitherapeutics.com